Neurocrine Biosciences (NBIX): Reiterate Top Mid Cap Pick - BMO

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after the company released abstracts for the American Society of Reproductive Medicine conference (October 15-19).

The analyst stated that the abstracts reinforce elagolix's strong efficacy profile in women with endometriosis, showing significant improvements on endometrial-associated pain, endometrial morphology, and quality of life observed on treatment. He believes the data continues to support approval for elagolix’s low- and high-doses, and his $1.0B peak sales estimate in endometriosis, with an additional blockbuster opportunity in uterine fibroids ($2.7B peak sales).

No change to the price target of $66.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $54.16 yesterday.

You May Also Be Interested In

• Wells Fargo Downgrades Canada Goose (GOOS:CN) (GOOS) to Underweight
• CTS Eventim (EVD:GR) PT Raised to EUR100 at Deutsche Bank
• Wells Fargo Starts Whirlpool Corporation (WHR) at Equal Weight